Novel pyrimidine-2,4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by targeting aurora kinases

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 436-445

  Salmela, Anna Leena ^a,b   Pouwels, Jeroen ^a   Mäki Jouppila, Jenni ^a,b,c   Kohonen, Pekka ^a   Toivonen, Pauliina ^a   Kallio, Lila ^a   Kallio, Marko ^a,b,d  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Drug Discovery and Toxicology Section   (Finland)

^d ACADEMY OF FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; 5 FLUORO 2 N,4 N DIPHENYLPYRIMIDINE 2,4 DIAMINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; CYCLIN B1; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; TUBULIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL KILLING; CELL VIABILITY; CENTROMERE; CHROMOSOME SEGREGATION; CONTROLLED STUDY; CYTOKINESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MITOTIC SPINDLE APPARATUS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84873558160     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs339     Document Type: Article

References (30)

1. Maresca,T.J. et al. (2010) Welcome to a new kind of tension: translating kinetochore mechanics into a wait-anaphase signal. J. Cell. Sci., 123(Pt 6), 825-835.
2. Musacchio,A. (2011) Spindle assembly checkpoint: the third decade. Philos. Trans. R. Soc. Lond., B, Biol. Sci., 366, 3595-3604.
3. Kops,G.J. et al. (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl. Acad. Sci. U.S.A., 101, 8699-8704.
4. Weaver,B.A. et al. (2008) Low rates of aneuploidy promote tumorigenesis while high rates of aneuploidy cause cell death and tumor suppression. Cell. Oncol., 30, 453.
5. Schmidt,M. et al. (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updat., 10, 162-181.
6. Zhou,J. et al. (2005) Targeting microtubules for cancer chemotherapy. Curr. Med. Chem. Anticancer. Agents, 5, 65-71.
7. Salmela,A.L. et al. (2012) The flavonoid eupatorin inactivates the mitotic checkpoint leading to polyploidy and apoptosis. Exp. Cell Res., 318, 578-592.
8. Salmela,A.L. et al. (2009) Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis, 30, 1032-1040.
9. Pouwels,J. et al. (2007) Shugoshin 1 plays a central role in kinetochore assembly and is required for kinetochore targeting of Plk1. Cell Cycle, 6, 1579-1585.
10. DeMoe,J.H. et al. (2009) A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor. Cancer Res., 69, 1509-1516.
11. Musacchio,A. et al. (2007) The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol., 8, 379-393.
12. Potapova,T.A. et al. (2009) Fine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit. Mol. Biol. Cell, 20, 1737-1748.
13. Skoufias,D.A. et al. (2007) Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed. J. Cell Biol., 179, 671-685.
14. Mayer,T.U. et al. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science, 286, 971-974.
15. Elowe,S. (2011) Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint. Mol. Cell. Biol., 31, 3085-3093.
16. Ditchfield,C. et al. (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol., 161, 267-280.
17. Hauf,S. et al. (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol., 161, 281-294.
18. Lens,S.M. et al. (2003) The survivin/Aurora B complex: its role in coordinating tension and attachment. Cell Cycle, 2, 507-510.
19. Girdler,F. et al. (2008) Molecular basis of drug resistance in aurora kinases. Chem. Biol., 15, 552-562.
20. Walter,A.O. et al. (2000) The mitotic serine/threonine kinase Aurora2/ AIK is regulated by phosphorylation and degradation. Oncogene, 19, 4906-4916.
21. Zeitlin,S.G. et al. (2001) CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J. Cell Biol., 155, 1147-1157.
22. Yasui,Y. et al. (2004) Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis. J. Biol. Chem., 279, 12997-13003.
23. Vader,G. et al. (2008) The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta, 1786, 60-72.
24. Kollareddy,M. et al. (2008) Aurora kinases: structure, functions and their association with cancer. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub., 152, 27-33.
25. Mountzios,G. et al. (2008) Aurora kinases as targets for cancer therapy. Cancer Treat. Rev., 34, 175-182.
26. Cheung,C.H. et al. (2009) Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin. Investig. Drugs, 18, 379-398.
27. Lens,S.M. et al. (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer, 10, 825-841.
28. Hornick,J.E. et al. (2008) Live-cell analysis of mitotic spindle formation in taxol-treated cells. Cell Motil. Cytoskeleton, 65, 595-613.
29. Aliagas-Martin,I. et al. (2009) A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. J. Med. Chem., 52, 3300-3307.
30. Wang,S. et al. (2010) Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J. Med. Chem., 53, 4367-4378.